A Placebo-Controlled Trial of Interferon Gamma-1b in Patients with Idiopathic Pulmonary Fibrosis
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Idiopathic pulmonary fibrosis is a progressive, fatal disease with no known efficacious therapy. METHODS: In a double-blind, multinational trial, we randomly assigned 330 patients with idiopathic pulmonary fibrosis that was unresponsive to corticosteroid therapy to receive subcutaneous interferon gamma-1b or placebo. RESULTS: Over a median of 58 weeks, interferon gamma-1b therapy did not significantly affect the primary end point of progression-free survival, defined as the time to disease progression or death, and no significant treatment effect was observed on measures of lung function, gas exchange, or the quality of life. Ten percent of patients in the interferon gamma-1b group died, as compared with 17 percent of patients in the placebo group (P=0.08). Treatment with interferon gamma-1b was associated with more frequent constitutional symptoms. However, the rates of treatment adherence and premature discontinuation of treatment were similar in the two groups. More pneumonias were reported among patients in the interferon gamma-1b group, but the incidence of severe or life-threatening respiratory tract infections was similar in the two groups. CONCLUSIONS: In a well-defined population of patients with idiopathic pulmonary fibrosis, interferon gamma-1b did not affect progression-free survival, pulmonary function, or the quality of life. Owing to the size and duration of the trial, a clinically significant survival benefit could not be ruled out.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, systemic administration of recombinant IFNγ (which would simulate the presence of Th1 biology) and monoclonal antibody-mediated neutralization of IL-13 (which would specifically target Th2 responses) failed to demonstrate efficacy in randomized, placebo-controlled trials of patients with IPF (141, 142).”
From The Role of Immune and Inflammatory Cells in Idiopathic Pulmonary Fibrosis (2018) · cites this paper as [141]
Citations
Cites
(2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.165.2.ats01 · Cited by 4,196
Idiopathic Pulmonary Fibrosis: Diagnosis and Treatment: International Consensus Statement
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.2.ats3-00 · Cited by 2,628
Nathan, C. F., Murray, H. W., Wiebe, M. E., & Rubin, B. Y. (1983) · The Journal of experimental medicine · doi:10.1084/jem.158.3.670 · Cited by 1,962
Mahler, D. A., Weinberg, D. H., Wells, C. K., & Feinstein, A. R. (1984) · Chest · doi:10.1378/chest.85.6.751 · Cited by 1,292
Prognostic Significance of Histopathologic Subsets in Idiopathic Pulmonary Fibrosis
BJORAKER, J. A., RYU, J. H., EDWIN, M. K., MYERS, J. L., TAZELAAR, H. D., SCHROEDER, D. R., & OFFORD, K. P. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.1.9704130 · Cited by 1,039
Editorial: Cerebral Palsy—the International Consensus Statement
Clements, R. V., & Simanowitz, A. (2000) · Clinical Risk · doi:10.1177/135626220000600401 · Cited by 856
Predicting Survival in Idiopathic Pulmonary Fibrosis
KING, T. E., TOOZE, J. A., SCHWARZ, M. I., BROWN, K. R., & CHERNIACK, R. M. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.164.7.2003140 · Cited by 853
Self-citationinternational consensus statement
Clements, R. V., & Simanowitz, A. (2000) · Cited by 852
Gajewski, T. F., & Fitch, F. W. (1988) · The Journal of Immunology · doi:10.4049/jimmunol.140.12.4245 · Cited by 834
Broekelmann, T. J., Limper, A. H., Colby, T. V., & McDonald, J. A. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.15.6642 · Cited by 794
Research works printed but not linked: 1
- Okada T, 1993, Lymphokine Cytokine Res, 12, 87
Cited by
Items 401–500 of 649
Kürner, T. (2014) · Respiratory Investigation · doi:10.1016/j.resinv.2014.09.001 · Cited by 12
“[5] Raghu G, Brown KK, Bradford WZ, et al.”
BackgroundResultTargeting the myofibroblast to improve wound healing
Hinz, B. (2016) · Elsevier eBooks · doi:10.1016/b978-1-78242-455-0.00003-3 · Cited by 13
Fibrose pulmonaire idiopathique
Cottin, V., & Cordier, J.-F. (2008) · La Presse Médicale · doi:10.1016/j.lpm.2008.01.024 · Cited by 12
New Developments in the Therapy of Pulmonary Fibrosis
Scriabine, A., & Rabin, D. U. (2009) · Advances in pharmacology · doi:10.1016/s1054-3589(08)57011-6 · Cited by 14
Idiopathic Interstitial Pneumonias
King, T. E. (2006) · Humana Press eBooks · doi:10.1007/978-1-59259-963-9_21 · Cited by 12
Self-citationManagement of Idiopathic Pulmonary Fibrosis
Cerri, S., Spagnolo, P., Luppi, F., & Richeldi, L. (2011) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2011.11.005 · Cited by 13
Ionescu, M. D., POPESCU, N. A., Stanescu, D., Enculescu, A. C., Bălgrădean, M., Căpitănescu, G. M., & Bumbăcea, D. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11226736 · Cited by 11
“IFN-γ (antifibrotic, anti-infective, antiproliferative, and immunomodulatory agent) and pirfenidone (antifibrotic agent) have obtained encouraging results [31,34].”
ResultClinical trials of investigational agents for IPF: a review of a Cochrane report
Richeldi, L. (2013) · Respiratory Research · doi:10.1186/1465-9921-14-s1-s4 · Cited by 12
“, was negative for efficacy in terms of the overall survival endpoint [14], whereas the smaller trial almost demonstrated statistical significance [15].”
MethodResultXia, Y., Lei, C., Yang, D., & Luo, H. (2020) · PeerJ · doi:10.7717/peerj.9848 · Cited by 11
“Althoughmulticenter trials of anti-inflammatory drugs for IPF treatment have failed (Farrand et al., 2020; King et al., 2009; Raghu et al., 2004; Raghu et al., 2017; Raghu et al., 2008), the immune system continues to be regarded as playing an important role in the development of fibrosis (Heukels et al.”
BackgroundLuzina, I. G., & Atamas, S. P. (2008) · Springer eBooks · doi:10.1007/978-1-84800-165-7_41 · Cited by 13
Idiopathic Pulmonary Fibrosis is Associated with Circulating Antiepithelial Antibodies
Fahim, A., Chong, M. C., Crooks, M. G., & Hart, S. P. (2012) · Lung · doi:10.1007/s00408-012-9390-z · Cited by 11
“It is a disease of dismal prognosis [1], and there are no effective disease modifying treatments available as yet [2–5].”
BackgroundTreating IPF—all or nothing? A PRO‐CON debate
Behr, J., Kolb, M. R. J., & Cox, G. (2009) · Respirology · doi:10.1111/j.1440-1843.2009.01645.x · Cited by 11
Interstitial lung disease: trials and tribulations
Afshar, K., & Sharma, O. P. (2008) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0b013e3283043e58 · Cited by 12
Evolving Concepts in the Early and Accurate Diagnosis of Idiopathic Pulmonary Fibrosis
du Bois, R. M. (2006) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2005.08.001 · Cited by 11
Antibiotic Prophylaxis for Chronic Obstructive Pulmonary Disease
Kunisaki, K. M., & Niewoehner, D. E. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200808-1315ed · Cited by 11
Consensus document for the diagnosis and treatment of idiopathic pulmonary fibrosis
Cordeiro, C. R., Campos, P., Carvalho, L., Campainha, S., Clemente, S., Figueiredo, L., Jesus, J. M., Marqués, J., Souto-Moura, C., Basto, R. P., et al. (2016) · Revista Portuguesa de Pneumologia · doi:10.1016/j.rppnen.2016.01.003 · Cited by 19
Chai, G., Tan, T. C., Lee, Y., Kaw, G. J. L., Kl, C., Lim, Y., Abisheganaden, J. A., & Thong, B. Y. (2019) · Singapore Medical Journal · doi:10.11622/smedj.2019069 · Cited by 11
Rethinking Idiopathic Pulmonary Fibrosis
Oldham, J. M., & Vancheri, C. (2021) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2021.03.005 · Cited by 13
Acute Exacerbations in Idiopathic Pulmonary Fibrosis
Martínez, F. J. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-3-200602070-00015 · Cited by 10
Cottin, V., Bonniaud, P., Cadranel, J. L., Crestani, B., Jouneau, S., Marchand-Adam, S., Nunès, H., Wémeau-Stervinou, L., Bergot, E., Blanchard, É., et al. (2022) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2022.01.014 · Cited by 14
Role of proteomics in the investigation of pulmonary fibrosis
Govender, P., Baugh, J. A., Pennington, S. R., Dunn, M. J., & Donnelly, S. C. (2007) · Expert Review of Proteomics · doi:10.1586/14789450.4.3.379 · Cited by 11
Therapeutic Management of Idiopathic Pulmonary Fibrosis: An Evidence-Based Approach
Nathan, S. D. (2006) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2005.08.004 · Cited by 10
Suplatast Tosilate Prevents Bleomycin-Induced Pulmonary Fibrosis in Mice
Furonaka, M., Hattori, N., Tanimoto, T., Senoo, T., Ishikawa, N., Fujitaka, K., Haruta, Y., Yokoyama, A., & Kohno, N. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.141721 · Cited by 10
“A recent meta-analysis study showed IFN- therapy to be associated with a reduced mortality (Bajwa et al., 2005); however, a randomized controlled trial involving 330 patients failed to show any clear benefit from IFN- therapy in comparison with a placebo (Raghu et al., 2004; King et al., 2005).”
P-Values on Trial: Selective Reporting of (Best Practice Guides Against) Selective Reporting
Mayo, D. G. (2020) · Harvard Data Science Review · doi:10.1162/99608f92.e2473f6a · Cited by 12
Enfermedades pulmonares intersticiales difusas
Xaubet, A., Molina‐Molina, M., & Sánchez, M. (2007) · Archivos de Bronconeumología · doi:10.1016/s0300-2896(07)71175-4 · Cited by 10
Nathan, S. D. (2005) · CHEST Journal · doi:10.1378/chest.128.5_suppl_1.533s · Cited by 10
Lung transplantation for interstitial lung disease
Lu, B. S., & Bhorade, S. M. (2004) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2004.04.008 · Cited by 11
“The median survival of biopsyproven IPF is less than 3 years [21], and currently no therapy has been shown clearly to improve morbidity or mortality [22–25].”
BackgroundInterferon Gamma-1b in the Treatment of Idiopathic Pulmonary Fibrosis
Pacanowski, M. A., & Amsden, G. W. (2005) · Annals of Pharmacotherapy · doi:10.1345/aph.1e672 · Cited by 11
Prevention of hepatic fibrosis in nonobese diabetic mice: a critical role for interferon‐γ
Mukai, T., Nagaki, M., Imose, M., Kimura, K., Satake, S., Takai, S., & Moriwaki, H. (2006) · Liver International · doi:10.1111/j.1478-3231.2006.01322.x · Cited by 11
Thabut, G., Crestani, B., Porcher, R., & Richeldi, L. (2015) · European Respiratory Journal · doi:10.1183/13993003.02204-2014 · Cited by 10
Is Idiopathic Pulmonary Fibrosis Now Treatable?
du Bois, R. M. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2502001 · Cited by 10
Risk of Surgical Lung Biopsy in Idiopathic Interstitial Pneumonias
Riley, D. J. (2005) · CHEST Journal · doi:10.1378/chest.127.5.1485 · Cited by 10
Etanercept for Idiopathic Pulmonary Fibrosis: Lessons on Clinical Trial Design
Jackson, R. M., & Fell, C. D. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200808-1223ed · Cited by 10
Disease Progression in Idiopathic Pulmonary Fibrosis. FVC Is Not Enough
Behr, J. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201706-1246ed · Cited by 11
Management of interstitial lung disease in elderly patients
Meyer, K. C. (2012) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0b013e3283541337 · Cited by 10
“Although posthoc analysis of the GIPF-1 study of interferon (IFN)-g1b suggested benefit for patients with less severe physiologic impairment [73], the more robustly powered INSPIRE trial showed no benefit for IFN-g1b as an antifibrotic therapy for IPF [74].”
MethodΤzouvelekis, Α., Karampitsakos, Τ., Bouros, E., Tzilas, V., Liossis, S. C., & Bouros, D. E. (2019) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2019.06.002 · Cited by 9
Pathophysiological conditions induced by SARS-CoV-2 infection reduce ACE2 expression in the lung
Miura, Y., Ohkubo, H., Nakano, A., Bourke, J. E., & Kanazawa, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1028613 · Cited by 9
“Therefore, IFN treatment may lead to a therapeutic approach as an anti-fibrosis agent if it can block the function of de novo IL-6; otherwise, it is less effective (44).”
BackgroundAdvances in the management of idiopathic pulmonary fibrosis
Ryu, J. H., & Daniels, C. E. (2010) · F1000 Medicine Reports · doi:10.3410/m2-28 · Cited by 10
“This initial enthusiasm was tempered when a randomized, double-blind, placebo-controlled clinical trial of 330 IPF patients showed no difference between placebo and gamma-interferon groups in progression-free survival, pulmonary function, or quality of life outcome measures [12].”
BackgroundKing, T. E. (2004) · PubMed · Cited by 10
Self-citationUse of biologics to treat acute exacerbations and manage disease in asthma, COPD and IPF
Murray, L. A., Grainge, C., Wark, P. A. B., & Knight, D. A. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.11.003 · Cited by 12
IL-10: another therapeutic target in idiopathic pulmonary fibrosis?
Millar, A. (2006) · Thorax · doi:10.1136/thx.2006.060772 · Cited by 9
End of an ERA: Lessons from Negative Clinical Trials in Idiopathic Pulmonary Fibrosis
Noble, P. W., Richeldi, L., & Kaminski, N. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201105-0813ed · Cited by 9
Self-citationIs big beautiful? The continuing story of ADAM33 and asthma
Holgate, S. T., & Holloway, J. W. (2005) · Thorax · doi:10.1136/thx.2004.031385 · Cited by 10
(2024) · Springer eBooks · doi:10.1007/978-981-99-9283-6_1305 · Cited by 9
Okuno, D., Akiyama, Y., Sakamoto, N., Tokito, T., Yura, H., Kido, T., Ishimoto, H., Ishimatsu, Y., Takemoto, S., Takazono, T., et al. (2025) · Experimental Cell Research · doi:10.1016/j.yexcr.2025.114584 · Cited by 9
The diagnosis of idiopathic pulmonary fibrosis and its complications
Maher, T. M. (2008) · Expert Opinion on Medical Diagnostics · doi:10.1517/17530050802549484 · Cited by 8
Clinical Trials in IPF: What Are the Best Endpoints?
Spagnolo, P., Cocconcelli, E., & Cottin, V. (2018) · Respiratory medicine · doi:10.1007/978-3-319-99975-3_19 · Cited by 9
Fibrose pulmonaire idiopathique
Cordier, J.-F. (2009) · La Presse Médicale · doi:10.1016/j.lpm.2009.10.009 · Cited by 9
Recent clinical trials in idiopathic pulmonary fibrosis and the BUILD-1 study
Brown, K. M., & Wells, A. U. (2008) · European Respiratory Review · doi:10.1183/09059180.00010903 · Cited by 8
“The GIPF-001 trial was a randomised, double-blind, placebocontrolled study in 330 patients with IPF, which assessed the effect of IFN-c on progression-free survival, defined as the time-to-disease progression or death, as well as pulmonary function and QoL [ 8 ].”
MethodSelf-citationInterferon-γ-1b: Therapeutic Option in Advanced Idiopathic Pulmonary Fibrosis?
Kroegel, C., Mock, B., Hengst, U., & Reißig, A. (2004) · Respiration · doi:10.1159/000081772 · Cited by 8
Influência do biofármaco DNA-hsp65 na lesão pulmonar induzida por bleomicina
de Pádua, A. I., Silva, C. L., Ramos, S. G., Faccioli, L. H., & Martínez, J. A. B. (2008) · Jornal Brasileiro de Pneumologia · doi:10.1590/s1806-37132008001100002 · Cited by 8
Wedzicha, J. A. (2005) · Thorax · doi:10.1136/thx.2005.043190 · Cited by 8
Froidure, A., Joannes, A., Mailleux, A., & Crestani, B. (2016) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2016.1171140 · Cited by 7
Celada, S. I., Lim, C. X., Carisey, A. F., Ochsner, S. A., Deza, C. F. A., Rexie, P., de Frias, F. P., Castillo, R. E. C., Polverino, F., Hengstschläger, M., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.ade2581 · Cited by 7
Luppi, F., Losi, M., D’Amico, R., Fabbri, L. M., & Richeldi, L. (2009) · Sarcoidosis vasculitis and diffuse lung diseases · Cited by 7
The Role of Epithelial Cell Quality Control in Health and Disease of the Distal Lung
Beers, M. F., Nureki, S., & Mulugeta, S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-803809-3.00008-7 · Cited by 7
Gaertner, F. H., Babiuk, L. A., Moorlehem, E. V., Beskorwayne, T., Lee, S. L., Shutter, R. W., Armstrong, J. M., & Griebel, P. J. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2005.06.008 · Cited by 7
Thatcher, T. H., Sime, P. J., & Barth, R. K. (2005) · Experimental Lung Research · doi:10.1080/01902140591007218 · Cited by 8
Interferon gamma for idiopathic pulmonary fibrosis
Bouros, D. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60689-9 · Cited by 7
Lindeman, R. D. (2005) · Experimental Lung Research · doi:10.1080/01902140591005067 · Cited by 9
“Based on a recent large randomized, double-blind, placebo controlled trial in IPF, approximately 15% of patients with UIP experience overwhelming acute exacerbation during the course of their disease, and this is often the fatal event for those affected [37].”
BackgroundInfluentialPlasma cells: a feasible therapeutic target in pulmonary fibrosis?
Goodwin, A. T., Noble, P. W., & Tatler, A. L. (2022) · European Respiratory Journal · doi:10.1183/13993003.01748-2022 · Cited by 7
Self-citationPharmacological treatment in Idiopathic Pulmonary Fibrosis: current issues and future perspectives
Vancheri, C., Sciacca, E., Muscato, G., Spicuzza, L., Fruciano, M., Gili, E., Sambataro, G., Palmucci, S., & Libra, A. (2024) · Multidisciplinary Respiratory Medicine · doi:10.5826/mrm.2024.982 · Cited by 14
What Is on the Horizon for Treatments in Idiopathic Pulmonary Fibrosis?
Moua, T., Baqir, M., & Ryu, J. H. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13216304 · Cited by 9
Traitements médicamenteux de la fibrose pulmonaire idiopathique
Crestani, B., Marchand-Adam, S., & Schneider, S. (2005) · Revue de Pneumologie Clinique · doi:10.1016/s0761-8417(05)84815-1 · Cited by 6
Update on models of pulmonary fibrosis therapy for preclinical drug research
Antoniu, S. A., & Kolb, M. R. J. (2009) · Expert Opinion on Drug Discovery · doi:10.1517/17460440903186100 · Cited by 10
“Another trial examining the efficacy of IFN-γ1b given subcutaneously for 1 year in 330 progressive IPF patients showed a marginal improvement in survival, lung function or quality of life but therapy was also associated with a higher incidence of pneumonia [63].”
Opposing roles of leukotrienes and prostaglandins in fibrotic lung disease
Moore, B. B., & Peters-Golden, M. L. (2006) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2.1.87 · Cited by 6
A formula for predicting emphysema extent in combined idiopathic pulmonary fibrosis and emphysema
Wells, A. U., Jacob, J., Sverzellati, N., Cross, G., Barnett, J. L., Lauretis, A. D., Antoniou, K. M., Weycker, D. A., Atwood, M., Kirchgaessler, K.-U., et al. (2024) · Respiratory Research · doi:10.1186/s12931-023-02589-x · Cited by 6
Antoniu, S. A. (2005) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.14.11.1443 · Cited by 6
Acute Respiratory Failure after Interferon-γ Therapy in IPF
de Carvalho, C. R. R., Kairalla, R. A., Schettino, G. P. P., Crestani, B., & Valeyre, D. (2004) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.169.4.953 · Cited by 6
Targeting the endothelin pathway in the idiopathic pulmonary fibrosis: the role of bosentan
Antoniu, S. A. (2008) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.12.9.1077 · Cited by 6
Gaertner, F. H., Babiuk, L. A., Mutwiri, G., Armstrong, J. M., & Griebel, P. J. (2009) · Vaccine · doi:10.1016/j.vaccine.2008.12.049 · Cited by 6
Novel Aspects of Treatment for Interstitial Lung Diseases
Behr, J. (2007) · KARGER eBooks · doi:10.1159/000102632 · Cited by 6
Clinical trials in idiopathic pulmonary fibrosis: a framework for moving forward
Lederer, D. J. (2013) · European Respiratory Journal · doi:10.1183/09031936.00092713 · Cited by 7
The Challenges of Clinical Research in Orphan Diseases
Spagnolo, P., & du Bois, R. M. (2014) · Springer eBooks · doi:10.1007/978-1-4471-2401-6_2 · Cited by 5
Idiopathic Interstitial Pneumonias
Selman, M., Morrison, L. D., Noble, P. W., & King, T. E. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-4710-0.00057-2 · Cited by 8
Self-citationIdiopathic Pulmonary Fibrosis: The Epidemiology and Natural History of Disease
Tourin, O., Swigris, J. J., & Olson, A. L. (2013) · Humana Press eBooks · doi:10.1007/978-1-62703-682-5_2 · Cited by 5
New Treatments for Idiopathic Pulmonary Fibrosis
Meyer, K. C., & Modi, D. (2016) · Clinical Pulmonary Medicine · doi:10.1097/cpm.0000000000000166 · Cited by 5
Role of Immune Cells in the Initiation and Progression of Pulmonary Fibrosis
Soumyakrishnan, S., Ayariga, J. A., Sreepriya, M., & Sudhandiran, G. (2022) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.2023047301 · Cited by 5
A platform for comparing subgroup identification methodologies
Ruberg, S. J., Zhang, Y., Showalter, H., & Shen, L. (2023) · Biometrical Journal · doi:10.1002/bimj.202200164 · Cited by 6
“…“promising sub-groups” discovered in post hoc analyses that have subsequently failed in confirmatory trials (Kubota et al., 2017; Rothwell, 2005; Sun & Benet, 2020), but we will alert the reader to one notable example related to idiopathic pulmonary fibrosis (King et al., 2009; Raghu et al., 2004).”
BackgroundNicholson, A. G., & Rice, A. J. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9781139018760.013 · Cited by 5
Nishiyama, O., Saeki, S., Yamazaki, R., Sano, H., Iwanaga, T., Kume, H., & Tohda, Y. (2019) · Respiratory Investigation · doi:10.1016/j.resinv.2019.03.005 · Cited by 6
Fujioka, K., Kasahara, A., Kida, T., Fujii, W., Seno, T., Wada, M., Kohno, M., & Kawahito, Y. (2022) · Allergy Asthma and Clinical Immunology · doi:10.1186/s13223-022-00703-0 · Cited by 5
Pharmacotherapy in patients with idiopathic pulmonary fibrosis
Nagai, S., Handa, T., & Kim, D. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.11.1909 · Cited by 5
Yun, A. J., Lee, P. Y., & Gerber, A. N. (2006) · American Journal of Roentgenology · doi:10.2214/ajr.05.0072 · Cited by 5
Wilcox, M. E., Rivera, M. P., Sassoon, C. S. H., Ware, L. B., Wunsch, H., & Herridge, M. S. (2012) · Proceedings of the American Thoracic Society · doi:10.1513/pats.201206-033tt · Cited by 5
Evaluating the Validity of Post-Hoc Subgroup Inferences: A Case Study
Lee, J. J., & Rubin, D. B. (2015) · The American Statistician · doi:10.1080/00031305.2015.1093961 · Cited by 6
“As such, IPF is debilitating and often fatal, with an estimated median survival time of two to three years after diagnosis (Raghu et al. 2004).”
BackgroundIdentifying Patients with Idiopathic Pulmonary Fibrosis
Richeldi, L., & Abraham, E. H. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200612-1873ed · Cited by 5
Fighting pulmonary fibrosis: new science brings new therapeutic opportunities
Das, A., Griswold, D. E., Molloy, C. J., Protter, A. A., & Laurent, G. J. (2004) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2004.11.007 · Cited by 5
Interferon Gamma-1b for Pulmonary Fibrosis
Tsoutsou, P. P., & Gourgoulianis, K. I. (2004) · New England Journal of Medicine · doi:10.1056/nejmc040311 · Cited by 5
Familial interstitial pulmonary fibrosis in two different families in India: A case series
Pradipkumar, D., Gautham, A., Gupta, R., James, P., Thangakunam, B., & Christopher, D. J. (2017) · Lung India · doi:10.4103/0970-2113.213824 · Cited by 4
Pharmacological Treatment of Idiopathic Pulmonary Fibrosis
Spagnolo, P., Luppi, F., Montanari, G., & Richeldi, L. (2013) · Humana Press eBooks · doi:10.1007/978-1-62703-682-5_14 · Cited by 4
The preventive role of levosimendan against bleomycin-induced pulmonary fibrosis in rats
Gürbüzel, M., Sayar, İ., Çankaya, M., Gürbüzel, A., Demirtaş, L., Bakırcı, E. M., & Çapoğlu, İ. (2015) · Pharmacological Reports · doi:10.1016/j.pharep.2015.10.001 · Cited by 4
Chermansky, C., Mitsogiannis, I. C., Abrams, P., & Apostolidis, A. (2019) · Neurourology and Urodynamics · doi:10.1002/nau.24069 · Cited by 5
Wuyts, W. A., Antin-Ozerkis, D. E., Huggins, J. T., LaCamera, P. P., Spagnolo, P., Vašáková, M., Wijsenbeek, M. S., Polman, B., Kirchgaessler, K.-U., & Scholand, M. B. (2019) · Respiratory Medicine · doi:10.1016/j.rmed.2019.02.021 · Cited by 5
“In INSPIRE and the pirfenidone trials, ≥50% of patients had underlying gastrointestinal disorders, metabolism and nutrition disorders, musculoskeletal and connective tissue disorders, vascular disorders, and respiratory, thoracic, and mediastinal disorders (Supplemental Table 4).”
BackgroundInfluentialEffect of treatment guidelines on the initial management of idiopathic pulmonary fibrosis
Munson, J. C., Kreider, M. E., Chen, Z., Christie, J. D., & Kimmel, S. E. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03670.x · Cited by 6
Relief from Within: A Peptide Therapy for Fibrosis
Atamas, S. P. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004138 · Cited by 4
Fibrose pulmonar idiopática: uma década de progressos
Swigris, J. J., & Brown, K. K. (2006) · Jornal Brasileiro de Pneumologia · doi:10.1590/s1806-37132006000300012 · Cited by 7
Self-citationClassification, natural history and staging of idiopathic pulmonary fibrosis.
Poletti, V. E., & Egan, J. J. (2013) · Sarcoidosis vasculitis and diffuse lung diseases · Cited by 5
Experimental therapeutic approaches to peripheral nerve tumors
Riley, J. R., Spiotta, A. M., & Boulis, N. M. (2007) · Neurosurgical FOCUS · doi:10.3171/foc.2007.22.6.3 · Cited by 4
Pneumopathies interstitielles diffuses idiopathiques
Cottin, V., Thivolet-Béjui, F., & Cordier, J. F. (2006) · Encyclopédie médico-chirurgicale. Pneumologie · doi:10.1016/s1155-195x(06)39806-4 · Cited by 6
Metadata
- Authors
- Raghu, G., Brown, K. K., Bradford, W. Z., Starko, K., Noble, P. W., Schwartz, D. A., & King, T. E.
- Affiliations
- University of Washington (US)
- National Jewish Health (US)
- Yale University (US)
- Duke University (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-01-08
- Volume
- 350
- Issue
- 2
- Pages
- 125-133
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2108226118
- Cited by
- 652
- References
- 34
- Citations by year
- 2026: 5 · 2025: 7 · 2024: 8 · 2023: 15 · 2022: 15 · 2021: 16 · 2020: 15 · 2019: 17 · 2018: 11 · 2017: 22 · 2016: 21 · 2015: 29 · 2014: 20 · 2013: 38 · 2012: 39
- FWCI
- 54.19
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Keywords
- idiopathic pulmonary fibrosis, interferon gamma-1b, progression-free survival, corticosteroid-refractory disease, lung function, quality of life, mortality, pneumonia, constitutional symptoms, medication adherence
- MeSH terms
- Double-Blind Method, Female, Humans, Injections, Subcutaneous, Interferon-gamma, Male, Middle Aged, Pulmonary Fibrosis, Recombinant Proteins, Respiratory Function Tests, Respiratory Tract Infections, Risk, Proportional Hazards Models, Treatment Failure, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.